Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial

Journal of Diabetes and its Complications

Volumn 31, Issue 1, 2017, Pages 1-3

  Katsiki, Niki ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRIACYLGLYCEROL;

BLOOD PRESSURE; BRAIN ISCHEMIA; DIABETIC PATIENT; EDITORIAL; HOSPITALIZATION; HUMAN; INSULIN RESISTANCE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT;

BRAIN ISCHEMIA; HUMANS; INSULIN RESISTANCE; ISCHEMIC ATTACK, TRANSIENT; PIOGLITAZONE; STROKE;

EID: 85005965315     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.09.005     Document Type: Editorial

References (33)

1. Athyros, V.G., Tziomalos, K., Katsiki, N., Doumas, M., Karagiannis, A., Mikhailidis, D.P., Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology 21 (2015), 6820–6834.
2. Barb, D., Portillo-Sanchez, P., Cusi, K., Pharmacological management of nonalcoholic fatty liver disease. Metabolism 65 (2016), 1183–1195.
3. Chiarelli, F., Di Marzio, D., Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vascular Health and Risk Management 4:2 (2008), 297–304.
4. Davidson, M., Meyer, P.M., Haffner, S., Feinstein, S., D'Agostino, R. Sr., Kondos, G.T., Mazzone, T., Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 117 (2008), 2123–2130.
5. DeFronzo, R.A., Tripathy, D., Schwenke, D.C., Banerji, M., Bray, G.A., Buchanan, T.A., ACT NOW Study, Pioglitazone for diabetes prevention in impaired glucose tolerance. The New England Journal of Medicine 364 (2011), 1104–1111.
6. Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., Taton, J., Secondary prevention of macrovascular events in patients with Type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events). Lancet 366 (2005), 1279–1289.
7. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59 (2016), 1121–1140.
8. Habib, Z.A., Tzogias, L., Havstad, S.L., Wells, K., Divine, G., Lanfear, D.E., Williams, L.K., Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiology and Drug Safety 18 (2009), 437–447.
9. Hamann, C., Kirschner, S., Günther, K.P., Hofbauer, L.C., Bone, sweet bone-osteoporotic fractures in diabetes mellitus. Nature Reviews. Endocrinology 8:5 (2012), 297–305.
10. Hernandez, A.V., Usmani, A., Rajamanickam, A., Moheet, A., Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. American Journal of Cardiovascular Drugs 11 (2011), 115–128.
11. Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 65 (2016), 1109–1123.
12. Kernan, W.N., Inzucchi, S.E., Viscoli, C.M., Brass, L.M., Bravata, D.M., Shulman, G.I., Horwitz, R.I., Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 34 (2003), 1431–1436.
13. Kernan, W.N., Viscoli, C.M., Furie, K.L., Young, L.H., Inzucchi, S.E., Gorman, M., IRIS Trial Investigators, Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. The New England Journal of Medicine 374 (2016), 1321–1331.
14. Lai, S.W., Lin, H.F., Lin, C.L., Liao, K.F., Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes: A case-control study in Taiwan. Medicine (Baltimore), 95, 2016, e4455.
15. Lewis, J.D., Habel, L.A., Quesenberry, C.P., Strom, B.L., Peng, T., Hedderson, M.M., Ferrara, A., Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA 314 (2015), 265–277.
16. Lincoff, A.M., Wolski, K., Nicholls, S.J., Nissen, S.E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007), 1180–1188.
17. Mannucci, E., Monami, M., Lamanna, C., Gensini, G.F., Marchionni, N., Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes, Obesity & Metabolism 10 (2008), 1221–1238.
18. Nagajothi, N., Adigopula, S., Balamuthusamy, S., Velazquez-Cecena, J.L., Raghunathan, K., Khraisat, A., Benatar, D., Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. American Journal of Therapeutics 15 (2008), 506–511.
19. Nissen, S.E., Nicholls, S.J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Tuzcu, E.M., Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008), 1561–1573.
20. Radenkovic, M., Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications. Scientia Pharmaceutica 82 (2014), 709–721.
21. Riche, D.M., King, S.T., Bone loss and fracture risk associated with thiazolidinedione therapy. Pharmacotherapy 30:7 (2010), 716–727.
22. Rizos, C.V., Elisaf, M.S., Mikhailidis, D.P., Liberopoulos, E.N., How safe is the use of thiazolidinediones in clinical practice?. Expert Opinion on Drug Safety 8 (2009), 15–32.
23. Rizza, S., Cardellini, M., Porzio, O., Pecchioli, C., Savo, A., Cardolini, I., Federici, M., Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis 215 (2011), 180–183.
24. Saremi, A., Schwenke, D.C., Buchanan, T.A., Hodis, H.N., Mack, W.J., Banerji, M., Reaven, P.D., Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arteriosclerosis, Thrombosis, and Vascular Biology 33 (2013), 393–399.
25. Sugawara, A., Uruno, A., Matsuda, K., Saito-Ito, T., Funato, T., Saito-Hakoda, A., Ito, S., Effects of PPAR? agonists against vascular and renal dysfunction. Current Molecular Pharmacology 5:2 (2012), 248–254.
26. Tanaka, R., Yamashiro, K., Okuma, Y., Shimura, H., Nakamura, S., Ueno, Y., Urabe, T., Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study. Journal of Atherosclerosis and Thrombosis 22 (2015), 1305–1316.
27. Tolman, K.G., Fonseca, V., Dalpiaz, A., Tan, M.H., Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30 (2007), 734–743.
28. Turner, R.M., Kwok, C.S., Chen-Turner, C., Maduakor, C.A., Singh, S., Loke, Y.K., Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. British Journal of Clinical Pharmacology 78 (2014), 258–273.
29. Vaccaro, O., Masulli, M., Bonora, E., Del Prato, S., Giorda, C.B., Maggioni, A.P., TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial), Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases 22 (2012), 997–1006.
30. Wilcox, R., Bousser, M.G., Betteridge, D.J., Schernthaner, G., Pirags, V., Kupfer, S., PROactive Investigators, Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007), 865–873.
31. Yokoyama, H., Araki, S., Kawai, K., Hirao, K., Oishi, M., Sugimoto, K., Japan Diabetes Clinical Data Management Study Group, Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36). Diabetes Research and Clinical Practice 109 (2015), 485–492.
32. Yoshii, H., Onuma, T., Yamazaki, T., Watada, H., Matsuhisa, M., Matsumoto, M., PROFIT-J Study Group, Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. Journal of Atherosclerosis and Thrombosis 21 (2014), 563–573.
33. Zou, C., Hu, H., Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk. Vascular Health and Risk Management 9 (2013), 429–433.